Vimta Labs Limited (VIMTALABS) Q2 FY27 Financial Results: PAT ₹210 Cr & Revenue ₹1,129 Cr

· NSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
MetricValue
Revenue₹1,129 Cr
Net Profit (PAT)₹210 Cr
📢 Key Event
Vimta Labs announces Q1 FY27 unaudited financial results
🔄 What Changed
PAT margin declined to 18.6% from 18.9% YoY; EBITDA margin fell to 36.4% from 37.6% YoY
🔮 What's Next
Company expresses optimism about industry prospects and evolving business opportunities, citing strong capabilities and expanding service portfolio
💡 Investor Takeaway
Shareholders see resilient performance with modest growth and stable margins amid sector headwinds

Vimta Labs Limited reported Q1 FY27 total income of ₹1,129 crores, up 13.7% YoY, with PAT at ₹210 crores and PAT margin at 18.6%, reflecting stable profitability despite margin compression from 18.9% to 18.6%.

📄 View Original Announcement (PDF)

About Vimta Labs Limited (VIMTALABS)

Healthcare · Healthcare · Listed on NSE

Market Cap: ₹2,878.27 Cr P/E: 23.3 ROE: 19.2% ROCE: 24.3% Div Yield: 0.31%

View full VIMTALABS stock details →

📡 Get AI alerts when VIMTALABS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track VIMTALABS — Free

📊 More VIMTALABS filings

See all VIMTALABS filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when VIMTALABS files new disclosures

Track VIMTALABS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track VIMTALABS — Free

Free account · 2 AI queries/day